Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-2808 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| mRNA-2808 | EXPERIMENTAL | Participants will receive mRNA-2808. |
| Name | Type | Description |
|---|---|---|
| mRNA-2808 | DRUG | intravenous or subcutaneous |
Key Inclusion Criteria: * RRMM with prior exposure to a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD38) monoclonal antibody. * Measurable disease defined as at least 1 of the following: * Serum M-protein ≥0.5 grams/deciliter * Urine M-protei...
Top 20 of 25 competitors
mRNA-2808 is an investigational RNA therapy being developed by Moderna, Inc. for relapsed or refractory multiple myeloma, a cancer of plasma cells in the bone marrow. It is in Phase 1 clinical development and is not approved for any use. It is designed for patients whose disease has returned or stopped responding to prior treatment.
mRNA-2808 is being studied as a treatment for adults with relapsed or refractory multiple myeloma, meaning disease that has come back or has not responded to earlier therapies. It is an investigational agent in Phase 1 testing, so its use is currently limited to participants enrolled in the clinical trial.
mRNA-2808 is developed by Moderna, Inc., which trades on the Nasdaq under the ticker MRNA. Moderna is the sponsor of the Phase 1 study evaluating the therapy in relapsed or refractory multiple myeloma. The company is known for its messenger RNA platform, and mRNA-2808 is an RNA therapy from that pipeline.
mRNA-2808 is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA or any other regulatory agency. The single ongoing study is a Phase 1 trial that is currently recruiting participants with relapsed or refractory multiple myeloma.
mRNA-2808 is being evaluated in one clinical trial, NCT07116616, titled A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma. The Phase 1 trial is recruiting and plans to enroll 190 participants in the United States. It is an uncontrolled study open to adults aged 18 years and older.
No, mRNA-2808 is not FDA approved. It is an investigational RNA therapy in Phase 1 clinical development for relapsed or refractory multiple myeloma. The only human study of mRNA-2808 is the ongoing Phase 1 trial NCT07116616, which is currently recruiting participants and has not been completed.